ImmunityBio converts from Immunomedics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics

IBRX 2.139

+0.9%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Redman1234	2/20/2025 7:34:27 AM
	Read Replies (1) of 1229

BCG by itself is not a big revenue driver, but the new better recombinant combined with superior bladder cancer drug Anktiva is not something Urologists worldwide can turn a blind eye. I’m looking at EMA AA approval by April. UK NICE approval in March. Partnership UK/EMA my guess lined up with EMA approval. In 2023, the BCG vaccine sales market was valued at $97.22 million. The market is expected to grow to nearly $129.67 million by 2030. Explanation BCG (Bacille Calmette-Guérin) is a vaccine that prevents tuberculosis. Merck is the sole producer of BCG in the United States and many other countries. The BCG vaccine is on the World Health Organization's list of essential medicines. The BCG vaccine is popular in developing countries because it's the only vaccine available for TB. The market for BCG vaccines is driven by an increase in the prevalence of chronic diseases and awareness of early disease diagnosis.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next